Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring.

Front Endocrinol (Lausanne) · 2023 · PMC10353048 · PMID 37469980

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

3.3.2 ASCVD or MRF Empagliflozin demonstrated a clear trend favoring it over dapagliflozin (MD 1.45, 95% CI 1.00–2.120) and canagliflozin (MD 1.46, 95% CI 1.01–2.11) ( Supplementary Figure A [6 (b)] ).

also in 19,460 other papers

a positive trendno p-value reported

We could find a very similar trend in the VERTIS-CV trial, where despite not meeting the primary endpoint (MACE), the exploratory endpoint of CV death had a positive trend compared to DECLARE TIMI-58 and CANVAS program.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.